Literature DB >> 29509726

Migraine drug race turns its final corner, FDA decisions in sight.

Elie Dolgin.   

Abstract

Entities:  

Year:  2018        PMID： 29509726     DOI： 10.1038/nbt0318-207

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Fremanezumab for the Preventive Treatment of Chronic Migraine.

Authors:  Stephen D Silberstein; David W Dodick; Marcelo E Bigal; Paul P Yeung; Peter J Goadsby; Tricia Blankenbiller; Melissa Grozinski-Wolff; Ronghua Yang; Yuju Ma; Ernesto Aycardi
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

2.  Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP Mechanisms.

Authors:  Bianca N Mason; Eric A Kaiser; Adisa Kuburas; Maria-Cristina M Loomis; John A Latham; Leon F Garcia-Martinez; Andrew F Russo
Journal:  J Neurosci       Date:  2017-01-04       Impact factor: 6.167

3.  A second trigeminal CGRP receptor: function and expression of the AMY1 receptor.

Authors:  Christopher S Walker; Sajedeh Eftekhari; Rebekah L Bower; Andrea Wilderman; Paul A Insel; Lars Edvinsson; Henry J Waldvogel; Muhammad A Jamaluddin; Andrew F Russo; Debbie L Hay
Journal:  Ann Clin Transl Neurol       Date:  2015-04-01       Impact factor: 4.511
  3 in total
  1 in total

1.  First migraine-prevention antibody approved.

Authors: 
Journal:  Nat Biotechnol       Date:  2018-07-06       Impact factor: 54.908
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.